Zhejiang Jiangbei Pharmaceutical Co. Ltd.

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation empagliflozin tablets (10 mg, manufactured by Zhejiang Jiangbei Pharmaceutical Co., Ltd.) and the reference formulation empagliflozin tablets (Otangjing®, 10 mg, manufactured by Boehringer Ingelheim Pharma GmbH & Co. KG, certified by Boehringer Ingelheim International GmbH) in healthy adult study participants after a meal, and to evaluate the bioequivalence of the two formulations after oral administration after a meal. Secondary objective: To evaluate the safety of a single oral dose of the test and reference formulations of empagliflozin tablets after a meal in healthy study participants.

Primary objective: In accordance with relevant bioequivalence testing regulations, ezetimibe tablets (trade name: Ezetimibe, strength: 10mg) manufactured by MSD International GmbH (Singapore Branch) and licensed by ORGANON SINGAPORE PTE. LTD. were selected as the reference formulation. A postprandial administration bioequivalence study was conducted on the test formulation ezetimibe tablets (strength: 10mg) manufactured and supplied by Zhejiang Jiangbei Pharmaceutical Co., Ltd. The study aimed to compare whether the differences in the absorption rate and extent of the drug in the test formulation with those in the reference formulation were within acceptable limits, and to evaluate the bioequivalence of the two formulations under postprandial administration conditions. Secondary objective: To observe the safety of oral administration of the test formulation ezetimibe tablets (strength: 10mg) and the reference formulation ezetimibe tablets (trade name: Ezetimibe, strength: 10mg) to healthy participants.

Primary objective: In accordance with relevant bioequivalence testing regulations, ezetimibe tablets (trade name: Ezetimibe, strength: 10mg) manufactured by MSD International GmbH (Singapore Branch) and licensed by ORGANON SINGAPORE PTE. LTD. were selected as the reference formulation. A fasting-administered human bioequivalence study was conducted on the test formulation ezetimibe tablets (strength: 10mg) manufactured and supplied by Zhejiang Jiangbei Pharmaceutical Co., Ltd. The study compared the absorption rate and extent of the drug in the test formulation with those in the reference formulation to determine if the differences were within acceptable limits, and evaluated the bioequivalence of the two formulations under fasting administration conditions. Secondary objective: To observe the safety of oral administration of the test formulation ezetimibe tablets (strength: 10mg) and the reference formulation ezetimibe tablets (trade name: Ezetimibe, strength: 10mg) to healthy participants.